A drug called bevacizumab added to adjuvant chemotherapy did not improve outcomes for patients with a form of high-risk breast cancer, according to a study published in the Journal of Clinical Oncology.
A drug called palbociclib, used in combination with standard treatment, improved survival for women with hormone receptor-positive metastatic breast cancer.
In a recent clinical trial, a drug called apalutamide added to standard therapy slowed cancer progression in men with prostate cancer, while maintaining quality of life.
Metformin, an inexpensive diabetes drug, has been found to reduce the risk of heart attacks and strokes triggered by air pollution by reducing inflammation in the lungs that triggers clotting.
An oral therapy called ibudilast significantly reduced the rate of brain tissue loss in patients with progressive multiple sclerosis, according to the results of a phase II trial.
Scientists have developed the first example of a bioresorbable electronic medicine: an implantable, biodegradable wireless device that speeds nerve regeneration and improves the healing of a damaged nerve.
A novel chemotherapy regimen led to improved outcomes for older patients with Hodgkin lymphoma, similar to those of younger patients, according to a Northwestern Medicine clinical trial.
A behavioral program significantly reduced the sexual risk for HIV infection among young transgender women, according to a Northwestern Medicine clinical trial.
Scientists have shown they can predict which chronic pain patients will respond to a placebo pill based on brain anatomy and psychological characteristics.
A gene therapy delivers novel solution for treating serious blood disease. Read the story in Northwestern Medicine magazine.